资深药物研发科学家胡逸民博士加盟明度智云，任Zeeta研究院总经理兼首席科学官。

胡逸民博士本科毕业于北京大学化学系，博士毕业于斯坦福大学化学专业，并于哈佛大学进行了为期两年的博士后研究。胡博士在医药研发行业拥有超过十年新药早期发现及CMC开发经历，曾就职于葛兰素史克和罗氏研发，任药物化学高级研发及项目团队管理人员。加入明度前，曾任恒瑞医药CMC执行总监，负责从0到1建立并领导苏州小分子CMC研发平台。胡逸民博士承担过多个医药研发及产业化领域的重点科技项目，曾获得国内各个级别的多项荣誉，具有丰富的行业经验。

胡博士加入明度后将全面负责Zeeta研究院的运营和研发工作，为明度在新阶段的发展注入强劲动力，探索药物研发智能化的创新和变革。

Dr. Yimin Hu joined Mingdu Zhiyun as the head of Zeeta Research Institute and Chief Scientist Officer.

Dr. Hu received his bachelor’s degree from Peking University, and PhD degree in Chemistry from Stanford University. He continued Postdoc research in organic chemistry at Harvard University for two years. Dr. Hu has more than 10 years’ experience in drug discovery and CMC development. He worked at GSK China R&D Center and Roche Innovation Center Shanghai, as Scientist to Principal Scientist in Medicinal Chemistry from 2009-2017. Dr. Hu served as Executive Director of CMC and the head of Suzhou site for small molecule development at Jiangsu Hengrui Medicine Co.,Ltd. from 2017-2022. Dr. Hu has been responsible for top level government sponsored projects in the area of pharmaceutical development. He has also received many awards and honors at different levels.

Dr. Hu will oversee the operation of Zeeta Research Institute, and explore interdisciplinary innovations enhanced with digital technologies. His knowledge and experience in drug discovery and development will strengthen the research capability for Mingdu, and promote next stage digital transformations for the pharmaceutical industry.

明度智云CEO邢杰：

“非常高兴胡博士能加入明度并担任Zeeta研究院院长和首席科学官。结合胡博在医药领域多年的海内外研究经验，将进一步提升明度BT+IT+OT+DT的人才优势，加强公司Biological Technology领域的专业化团队建设，促进明度在创新研发方向探索的场景深度。明度也将继续做好生命科学领域数字化道路上一百米深的事情，践行“守护每一份药，守护每位患者”的使命，为推动行业数字化变革贡献力量。”